Amprion lands growth debt from Decathlon to scale brain-disease testing
What's the deal? Amprion, a San Diego diagnostics company, has secured a multi-million-dollar growth-debt investment from Decathlon Capital PartnersDealroom has a profile for this one. Try Dealroom →. The funding will expand its testing capacity for neurodegenerative diseases including Parkinson's, Lewy body dementia, and Alzheimer's.
What does Amprion do? It develops seed-amplification testing to diagnose neurodegenerative disorders. Its SAAmplify-aSYN assay aids diagnosis of synucleinopathies such as Parkinson's disease and Lewy body dementia.
Why debt? Decathlon provides growth capital as an alternative to equity, using customised financing that avoids dilution and loss of control. The structure lets Amprion fund expansion while preserving ownership and governance.
"The tailored financing package provides the operational flexibility needed to support our growth strategy while remaining non-dilutive to existing shareholders and preserving our management control and governance structure," said chief executive officer Russ LebovitzDealroom has a profile for this one. Try Dealroom →.
Why now? Lebovitz says demand for the tests is rising as researchers and clinicians look for reliable, pathology-based insights into Parkinson's and related conditions. The investment strengthens Amprion's ability to meet that demand and speed global adoption.
What's the endgame? Beyond diagnostics, Amprion is helping biopharma partners identify new drug candidates and underlying pathologies. It aims to expand access for physicians and researchers worldwide.
"Amprion is addressing a critical need in neurological care through its commitment to earlier and more accurate diagnosis of neurodegenerative diseases," said Matt Hoffman, managing director of Decathlon Capital Partners.
The signal: The deal reflects growing interest in early, biology-based diagnosis of neurodegenerative disease — and shows how non-dilutive debt is emerging as a scaling route for revenue-generating diagnostics firms wary of giving up equity.
Read more: Yahoo Finance
